Roughly 1% to 2% of children in the United States have a peanut allergy, making it one of the most common and most dangerous food allergies in the country. Among U.S. adults, about 3% report being allergic to peanuts, though when researchers dig into the details, closer to 1.8% have a convincing clinical history. Globally, the numbers vary dramatically depending on geography, diet, and how allergies are measured.
Peanut Allergy Rates in the U.S.
Peanut allergy affects an estimated 1% to 2% of American children, a rate that has been climbing over the past few decades. For adults, a large national survey found that 2.9% self-reported a peanut allergy, but when researchers evaluated the responses more carefully, only about 1.8% had symptoms and history consistent with a true allergy. That gap matters: many people believe they’re allergic based on a single reaction, a childhood test, or a family member’s experience, without ever being formally diagnosed.
Translating those percentages into raw numbers, somewhere between 2 and 6 million Americans likely have a genuine peanut allergy. Among children specifically, peanut is one of the top triggers for anaphylaxis, a severe whole-body allergic reaction that can be life-threatening without prompt treatment.
How Rates Differ Around the World
Peanut allergy prevalence is not evenly distributed. In Europe, North America, and Australia, peanuts rank among the most common causes of severe allergic reactions to food. Australia has some of the highest rates ever measured: a landmark study of infants in Melbourne found that 3% were allergic to peanuts, confirmed through oral food challenges rather than just skin tests or blood work.
In contrast, peanut allergy is extremely rare in many Asian countries, including Thailand and China. The reasons aren’t fully understood but likely involve a combination of genetics, how peanuts are prepared (boiled versus dry-roasted, for example), and how early and how often children are exposed to peanut-containing foods. In Asia and Latin America, shellfish and seafood allergies dominate instead.
Are Peanut Allergies Still Increasing?
For years, the prevailing advice was to keep peanuts away from babies and toddlers. That changed in 2017 when major guidelines shifted to recommend early introduction of peanut-containing foods, based on strong evidence that early exposure could prevent allergies from developing in the first place. The shift appears to be working, at least for the youngest children.
A study tracking pediatric anaphylaxis cases at a children’s hospital in Montreal from 2011 to 2019 found that after the 2017 guidelines were adopted, the rate of new peanut-triggered anaphylaxis in children aged 2 and younger dropped significantly. The yearly rate of change decreased by nearly 8 cases per year in that age group. Older children, ages 3 to 17, showed no significant change, which makes sense since they were past the window where early introduction would have made a difference. It’s still too early to declare victory, but the trend is encouraging.
Do Children Outgrow Peanut Allergies?
Peanut allergy has long been considered one of the more persistent food allergies, unlike milk or egg allergies, which most children outgrow. But the picture is more nuanced than “once allergic, always allergic.” Research published by the American Academy of Allergy, Asthma and Immunology found that 32.1% of infants who developed peanut allergy in their first year of life outgrew it by the time they reached their study follow-up, which varied between 3 and 5 years of age.
Resolution rates varied across the different study groups, ranging from about 19% to 54%, depending on the cohort and how early the children were exposed to peanuts. Children who had milder initial reactions and lower levels of allergy-related antibodies were more likely to outgrow it. Still, the majority of children with peanut allergy carry it into adolescence and adulthood, which is why long-term management matters.
How Peanut Allergy Is Diagnosed
One reason prevalence numbers are hard to pin down is that diagnosis isn’t straightforward. Skin prick tests, where a tiny amount of peanut protein is placed on the skin, are highly sensitive (catching about 93% of true allergies) but produce a lot of false positives. Blood tests that measure antibodies to a specific peanut protein called Ara h 2 are more precise, correctly identifying 92% of people who are not allergic and giving the best positive predictive value of any single test at 94%.
The gold standard remains an oral food challenge, where a patient eats increasing amounts of peanut under medical supervision. This is the only way to confirm whether someone will actually react, but it’s time-consuming, requires a clinical setting, and carries real risk. Because most studies rely on skin tests or blood work rather than food challenges, published prevalence numbers tend to overestimate the true rate of peanut allergy.
The Financial Burden on Families
Managing a food allergy is expensive. A comprehensive analysis estimated the total economic cost of childhood food allergies in the U.S. at $24 billion annually, which breaks down to roughly $4,077 per child per year. Direct medical costs, including doctor visits, emergency room trips, and hospitalizations, accounted for $3.7 billion. But the bigger expenses were less obvious: $5.5 billion in out-of-pocket costs to caregivers, nearly a third of which went toward specialty allergen-free foods, and a staggering $14 billion in lost opportunity costs from parents leaving jobs or reducing hours to manage their child’s allergy.
These figures cover all food allergies, not peanut alone, but peanut allergy is one of the most management-intensive because peanut protein shows up in so many processed foods and cross-contamination risks are high. The costs extend well beyond epinephrine auto-injectors. Families pay more for groceries, limit where they eat out, and often choose schools and childcare based on allergy policies.
Treatment Options Beyond Avoidance
For decades, the only strategy was strict avoidance and carrying emergency medication. That changed in 2020 when the FDA approved the first oral immunotherapy for peanut allergy, designed for patients ages 1 through 17. The treatment works by giving tiny, carefully measured amounts of peanut protein in gradually increasing doses over months, training the immune system to tolerate small exposures. It doesn’t cure the allergy. The goal is to reduce the severity of accidental reactions, not to let someone eat a peanut butter sandwich freely.
The treatment requires a significant commitment: months of escalating doses administered under medical supervision, followed by a daily maintenance dose taken at home indefinitely. Allergic reactions during treatment are common, and patients still need to carry emergency medication. It’s a meaningful option for families who want an extra layer of protection against accidental exposures, but it isn’t right for everyone.